Beigene share price today

(BGNE)

Beigene share price is $184.71 & ₹15,849.97 as on 1 Jan 2025, 2.30 'hrs' IST

$184.71

Market is closed - opens 8 PM, 07 Jan 2025

View live Beigene share price in Dollar and Rupees. Guide to invest in Beigene stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Beigene, along with analyst recommendations, forecasts, and comprehensive financials.

Beigene share price movements

Today's Low: $184.00
Today's High: $187.42
$184.71
0.38%
Downside
Day's Volatility :1.82%
Upside
1.45%
52 Weeks Low: $126.97
52 Weeks High: $248.16
$184.71
31.26%
Downside
52 Weeks Volatility :48.84%
Upside
25.57%

Beigene Returns

Period	Beigene Ltd	Sector (Health Care)	Index (Russel 2000)
3 Months	-21.54%	-8.4%	0.0%
6 Months	27.8%	-3.8%	0.0%
1 Year	7.68%	-0.1%	0.0%
3 Years	-22.77%	2.9%	-19.8%

Beigene Key Statistics

in dollars & INR

Previous Close	$184.71
Open	$184.0
Today's High	$187.42
Today's Low	$184.0
Market Capitalization	$20.5B
Today's Volume	$331.6K
52 Week High	$248.16
52 Week Low	$126.9681
Revenue TTM	$23.5B
EBITDA	$-5.6B
Earnings Per Share (EPS)	$-8.18
Profit Margin	-25.5%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-23.22%

How to invest in Beigene from India?

It is very easy for Indian residents to invest directly in Beigene from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Beigene stock in both Indian Rupees (INR) and US Dollars (USD). Search for Beigene or BGNE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Beigene or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Beigene shares which would translate to 0.005 fractional shares of Beigene as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Beigene, in just a few clicks!

Returns in Beigene for Indian investors in Rupees

Investment Value

₹1,00,000

Beigene investment value today

Current value as on today

₹1,10,900

Returns

₹10,900

(+10.9%)

Returns from Beigene Stock

₹7,678 (+7.68%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Beigene

-12.5%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Investment in Beigene from India has reduced in the last 30 days as on Jan 7, 2025. -12.5% less purchase transactions for Beigene in the last 30 days versus the previous period.

-18%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Beigene on INDmoney from India has reduced in the last 30 days as on Jan 7, 2025. -18% less investors are searching Beigene in the last 30 days versus the previous period.

Global Institutional Holdings in Beigene

Baker Bros Advisors LP
9.94%
Capital Research & Mgmt Co - Division 3
6.05%
Hillhouse Capital Advisors, Ltd.
4.87%
PRIMECAP Management Company
4.68%
Baillie Gifford & Co Limited.
3.49%
T. Rowe Price Associates, Inc.
2.54%

Analyst Recommendation on Beigene

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Beigene(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Beigene

What analysts predicted

Upside of 52.09%

Current:

$184.71

Target:

$280.92

Insights on Beigene

Price Movement
In the last 1 month, BGNE stock has moved down by -10.2%
Increasing Revenue
Revenue is up for the last 4 quarters, 634.40M → 1.00B (in $), with an average increase of 14.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -120.40M → -121.35M (in $), with an average decrease of 0.8% per quarter
BGNE vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 12.0%
BGNE vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 73.2%
Price to Sales
ForBGNE every $1 of sales, investors are willing to pay $0.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Beigene Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$198.2M	↓ 16.85%
Net Income	$-673.8M	↑ 623.67%
Net Profit Margin	-339.91%	↓ 300.85%

	FY19	Y/Y Change
Revenue	$428.2M	↑ 116.03%
Net Income	$-950.6M	↑ 41.08%
Net Profit Margin	-221.99%	↑ 117.92%

	FY20	Y/Y Change
Revenue	$308.9M	↓ 27.87%
Net Income	$-1.6B	↑ 68.37%
Net Profit Margin	-518.18%	↓ 296.19%

	FY21	Y/Y Change
Revenue	$1.2B	↑ 280.83%
Net Income	$-1.4B	↓ 11.69%
Net Profit Margin	-120.15%	↑ 398.03%

	FY22	Y/Y Change
Revenue	$1.4B	↑ 20.37%
Net Income	$-2.0B	↑ 41.78%
Net Profit Margin	-141.52%	↓ 21.37%

	FY23	Y/Y Change
Revenue	$2.5B	↑ 73.65%
Net Income	$-881.7M	↓ 56.0%
Net Profit Margin	-35.86%	↑ 105.66%

	Q2 FY23	Q/Q Change
Revenue	$595.3M	↑ 32.93%
Net Income	$-381.1M	↑ 9.39%
Net Profit Margin	-64.03%	↑ 13.78%

	Q3 FY23	Q/Q Change
Revenue	$781.3M	↑ 31.25%
Net Income	$215.4M	↓ 156.52%
Net Profit Margin	27.57%	↑ 91.6%

	Q4 FY23	Q/Q Change
Revenue	$634.4M	↓ 18.8%
Net Income	$-367.6M	↓ 270.63%
Net Profit Margin	-57.94%	↓ 85.51%

	Q1 FY24	Q/Q Change
Revenue	$751.7M	↑ 18.48%
Net Income	$-251.2M	↓ 31.67%
Net Profit Margin	-33.41%	↑ 24.53%

	Q2 FY24	Q/Q Change
Revenue	$929.2M	↑ 23.62%
Net Income	$-120.4M	↓ 52.06%
Net Profit Margin	-12.96%	↑ 20.45%

	Q3 FY24	Q/Q Change
Revenue	$1.0B	↑ 7.8%
Net Income	$-121.4M	↑ 0.78%
Net Profit Margin	-12.12%	↑ 0.84%

	FY18	Y/Y Change
Profit	$-509.5M	↑ 1330.95%

	FY19	Y/Y Change
Profit	$-570.3M	↑ 11.94%

	FY20	Y/Y Change
Profit	$-1.1B	↑ 85.28%

	FY21	Y/Y Change
Profit	$-447.9M	↓ 57.62%

	FY22	Y/Y Change
Profit	$-511.1M	↑ 14.11%

	FY23	Y/Y Change
Profit	$2.1B	↓ 506.77%

	Q2 FY23	Q/Q Change
Profit	$76.5M	↓ 79.1%

	Q3 FY23	Q/Q Change
Profit	$685.0M	↑ 795.34%

	Q4 FY23	Q/Q Change
Profit	$505.9M	↓ 26.15%

	Q1 FY24	Q/Q Change
Profit	$626.7M	↑ 23.89%

	Q2 FY24	Q/Q Change
Profit	$791.0M	↑ 26.22%

	Q3 FY24	Q/Q Change
Profit	$831.1M	↑ 5.07%

	FY18	Y/Y Change
Operating Cash Flow	$-547.7M	↓ 4395.15%
Investing Cash Flow	$-637.6M	↑ 78.94%
Financing Cash Flow	$1.7B	↑ 244.76%

	FY19	Y/Y Change
Operating Cash Flow	$-750.3M	↑ 36.98%
Investing Cash Flow	$554.2M	↓ 186.91%
Financing Cash Flow	$85.7M	↓ 94.93%

	FY20	Y/Y Change
Operating Cash Flow	$-1.3B	↑ 71.07%
Investing Cash Flow	$-3.2B	↓ 671.74%
Financing Cash Flow	$5.2B	↑ 5972.39%

	FY21	Y/Y Change
Operating Cash Flow	$-1.3B	↑ 1.19%
Investing Cash Flow	$640.7M	↓ 120.22%
Financing Cash Flow	$3.6B	↓ 30.1%

	FY22	Y/Y Change
Operating Cash Flow	$-1.5B	↑ 15.24%
Investing Cash Flow	$1.1B	↑ 68.13%
Financing Cash Flow	$-19.0M	↓ 100.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-293.9M	↓ 47.87%
Investing Cash Flow	$67.8M	↑ 0.0%
Financing Cash Flow	$166.1M	↓ 935.92%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-78.2M	↓ 73.41%
Investing Cash Flow	$-186.3M	↓ 374.74%
Financing Cash Flow	$-76.8M	↓ 146.23%

Beigene Technicals Summary

Sell

Neutral

Buy

Beigene is currently in a neutral trading position according to technical analysis indicators.

Beigene Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Beigene Ltd	-11.03%	27.8%	7.68%	-22.77%	10.31%
Regeneron Pharmaceuticals, Inc.	-8.86%	-31.87%	-20.46%	15.59%	87.28%
Biontech Se	-4.16%	43.82%	3.49%	-49.66%	167.6%
Alnylam Pharmaceuticals, Inc.	-8.45%	-8.03%	19.03%	56.02%	98.44%
Vertex Pharmaceuticals Incorporated	-14.11%	-16.23%	-2.87%	81.78%	76.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Beigene Ltd	NA	NA	0.0	-5.55	-0.23	-0.1	NA	226.72
Regeneron Pharmaceuticals, Inc.	17.61	17.61	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Beigene Ltd	Buy	$20.4B	10.31%	NA	-25.5%
Regeneron Pharmaceuticals, Inc.	Buy	$78.3B	87.28%	17.61	33.61%
Biontech Se	Buy	$27.3B	167.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.4B	98.44%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$103.7B	76.8%	32.84	-4.51%

Beigene Dividend announcements

Beigene Earnings
Beigene’s price-to-earnings ratio stands at None
Read More

About Beigene

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Organization	Beigene
Employees	10600
CEO	Mr. John V. Oyler
Industry	Health Technology

Management People of Beigene

Name	Title
Mr. John V. Oyler	Co-Founder, Executive Chairman & CEO
Dr. Xiaobin Wu Ph.D.	President & COO
Dr. Xiaodong Wang Ph.D.	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder
Mr. Chan Lee	General Counsel & Senior VP
Mr. Wang Lai Ph.D.	Global Head of R&D
Mr. Aaron Rosenberg	CFO & Principal Financial Officer
Mr. Titus B. Ball	VP & Chief Accounting Officer
Ms. Liza Heapes	Head of Investor Relations
Mr. Yang Ji	Chief Compliance Officer
Dr. Yan Qi	Senior VP & Head of Public Affairs - Greater China

Important FAQs about investing in Beigene from India :

What is Beigene share price today?

Beigene share price today stands at $184.71, Open: $184.00 ; Previous Close: $184.71 ; High: $187.42 ; Low: $184.00 ; 52 Week High: $248.16 ; 52 Week Low: $126.97. The stock opens at $184.00, after a previous close of $184.71. The stock reached a daily high of $187.42 and a low of $184.00, with a 52-week high of $248.16 and a 52-week low of $126.97.

Can Indians buy Beigene shares?

Yes, Indians can invest in the Beigene (BGNE) from India.

With INDmoney, you can buy Beigene at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Beigene at zero transaction cost.

How can I buy Beigene shares from India?

It is very easy to buy Beigene from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Beigene be purchased?

Yes, you can buy fractional shares of Beigene with INDmoney app.

What are the documents required to start investing in Beigene stocks?

To start investing in Beigene, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.